Research Collaboration and License Agreements - Narrative (Details) - USD ($)				1 Months Ended	3 Months Ended	12 Months Ended		15 Months Ended
	Mar. 31, 2022	Apr. 01, 2021	Mar. 31, 2021	Mar. 31, 2019	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2015	Mar. 31, 2022	Dec. 31, 2021	[1]
Collaborative Arrangement [Line Items]
Amount of additional fund received for research activities								$ 20,000,000
Related party revenue					$ 20,900,000
Related party contract asset	$ 0				0	$ 0		0
Contract liabilities	$ 5,117,000				5,117,000	5,117,000		5,117,000	$ 17,774,000
Proof-Of-Concept Trial, CVM Research
Collaborative Arrangement [Line Items]
Milestone payment for potential achievement of certain clinical development events					10,000,000
Merck Amended Agreement | Minimum
Collaborative Arrangement [Line Items]
Option exercise fee					40,000,000
Merck Amended Agreement | Maximum
Collaborative Arrangement [Line Items]
Option exercise fee					45,000,000
Merck Amended Agreement | Proof-Of-Concept Trial, CVM Research
Collaborative Arrangement [Line Items]
Option exercise fee					$ 6,000,000
Collaboration Agreement | Merck Sharp & Dohme Corp
Collaborative Arrangement [Line Items]
Company outstanding shares					16.60%
Share of global development costs percentage					25.00%
Merck Sharp & Dohme Corp | Merck Original Agreement
Collaborative Arrangement [Line Items]
Performance of R&D services period							5 years
Additional term	2 years		2 years		2 years		2 years
Amount of fund received for research activities				$ 75,000,000
Research collaboration and license agreements extension fee							$ 20,000,000
Merck Sharp & Dohme Corp | Merck Amended Agreement
Collaborative Arrangement [Line Items]
Additional term		3 years
Amount of fund received for research activities					$ 86,000,000	86,000,000
Research collaboration and license agreements extension fee					$ 20,000,000
Amount of additional fund received for research activities						20,000,000
Agreed-upon data package					60 days
Funded percentage of global development costs					50.00%
Remaining extension fee					$ 16,000,000
Required amount to expend					$ 35,000,000
Remaining extension term					2 years
Research and development performance obligation period					3 years
Transaction price for the two-year performance obligation	$ 125,500,000				$ 125,500,000	125,500,000		$ 125,500,000
Reimbursable expense						$ 19,500,000
Merck Sharp & Dohme Corp | Merck Amended Agreement | Minimum
Collaborative Arrangement [Line Items]
Reinvestment amount from option fee					5,000,000
Merck Sharp & Dohme Corp | Merck Amended Agreement | Maximum
Collaborative Arrangement [Line Items]
Reinvestment amount from option fee					15,000,000
Merck Sharp & Dohme Corp | Merck Amended Agreement | Proof-Of-Concept Trial, CVM Research
Collaborative Arrangement [Line Items]
Amount of fund received for research activities					$ 86,000,000

[1] The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date.